Cat | Cas | Eng
Previous issues
Digital newsletter of IDIBELL
Number 144 - 19 April 2016

Home > Calls
Alzheimer's Combination Therapy Opportunities (ACTO) Program - Funding Opportunities from ADDF
Identifier: 142/16
Categorie: Projectes de recerca
Financing entity: 328
OTRI deadline: 13/05/2016
Call aim:

The ADDF offers funding for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research. 

Alzheimer's Combination Therapy Opportunities (ACTO) Program: supports biomarker-based combination trials testing repurposed drug combinations from Phase 1 through Phase 2 proof of concept. Priority will be given to projects that:

  • Target biological mechanisms with a strong rationale for these mechanisms to be relevant in treating AD in combination, including but not limited to drugs that target multiple biological mechanisms
  • Explore the combination of two repurposed drugs; repurposing refers to studying compounds developed and/or approved to treat another disease or condition to determine safety/efficacy for treating other diseases
Duration: <p>2-3 years</p>
  • Applications will be accepted from academic investigators and small companies with candidate therapies ready for early phase human clinical trials. Applicants are required to assemble an interdisciplinary team, including but not limited to, biology, pharmacology and clinical trial experts.
  • Researchers with full- time staff or faculty appointments are encouraged to apply.
  • Applications from post- doctoral candidates will not be accepted.
  • Applications will be accepted from organizations around the world.
  • Both non-profit and small for-profit agencies are eligible.  Not-for-profit organizations must submit documentation verifying status for consideration during the letter of intent process.

All Letters of intent must be submitted online through Proposal Central.

Full applications must be received by August 10, 2016 and must be submitted online through Proposal Central.

More information:

Evaluation criteria:

  • Biological rationale for the combination to treat AD
  • Non-clinical team to define dose and evaluate the PK, safety and toxicity of the combination
  • Biomarker strategy which may include translatable biomarkers to provide data on target engagement
  • Clinical team to define the patient population, exclusion/inclusion criterial and clinical trial design
  • Regulatory expertise in order to gain NDA approval for the combination
  • Patent expertise to provide clarity on intellectual property issues for the combination of repurposed drugs
  • A strong and consistent source and supply for the drugs to be used in the program
Place of presentation:
Cofinancing by the institution: No
Specialist manager:
Date of expression of interest: 06/05/2016
OTRI deadline: 13/05/2016
Call deadline: 20/05/2016
Resolution date:
Budget advices (URL):
Calls (URL): Application website Proposal Central
Other documents: Pre-clinical drug discovery guidelines    Program to Accelerate Clinical Trials Guidelines    Application Instructions    Guidelines   

Legal notice | Contact